Diabetes Drugs Market Report by Drug Class, Diabetes Type, Route of Administration, Distribution Channel, Country and Company Analysis 2026-2034

Diabetes Drugs Market Size and Forecast

The global diabetes drugs market is projected to expand from US$ 82.84 billion in 2025 to US$ 120.07 billion by 2034, registering a CAGR of 4.21% during 2026–2034. Market growth is being supported by the increasing global prevalence of diabetes, improved disease diagnosis, and expanding access to modern treatment options. Growing adoption of innovative oral medications and injectable therapies, along with continuous pharmaceutical research and development, is further strengthening market demand. Rising healthcare expenditure, improved treatment accessibility in emerging economies, and advancements in diabetes management are also contributing to the market’s long-term expansion.

What are Diabetes Drugs and Their Uses & Popularity Worldwide?

Diabetes drugs are medications used to control blood glucose levels and manage diabetes, a chronic condition in which the body cannot produce sufficient insulin or cannot use insulin effectively. These medicines are available in several forms, including oral tablets, injectable therapies, and insulin preparations. Common categories include metformin, sulfonylureas, DPP-4 inhibitors, SGLT2 inhibitors, GLP-1 receptor agonists, and insulin, with treatment selected according to diabetes type, glucose levels, patient characteristics, and medical requirements. Diabetes drugs help lower blood glucose, improve insulin sensitivity or secretion, reduce the risk of diabetes-related complications, and support long-term disease management. Some newer therapies also provide cardiovascular and kidney-related benefits in appropriate patients.

The worldwide popularity of diabetes drugs is increasing because of the growing burden of diabetes, improved diagnosis, expanding healthcare access, and continuous pharmaceutical innovation. The International Diabetes Federation estimates that approximately 589 million adults aged 20–79 years were living with diabetes in 2024, with the number projected to reach around 853 million by 2050. Rising prevalence, greater treatment awareness, and increasing adoption of advanced oral and injectable therapies are therefore supporting demand for diabetes medications across developed and emerging markets.

Global Prevalence of Diabetes

* North America and Caribbean: 56 million

* Europe: 66 million

* Middle East and North Africa: 85 million

* South and Central America: 35 million

* Africa: 25 million

* South-East Asia: 107 million

* Western Pacific: 215 million

Growth Drivers of the Diabetes Drugs Market

Rising Global Prevalence of Diabetes

The rapidly increasing number of people living with diabetes is creating a large and expanding patient base for glucose-lowering medicines. According to the International Diabetes Federation (IDF), approximately 589 million adults aged 20–79 years were living with diabetes in 2024, equivalent to about one in nine adults globally. This figure is projected to reach 853 million by 2050, representing approximately one in eight adults. The burden is particularly significant in low- and middle-income countries, which account for around 81% of adults living with diabetes. In addition, approximately 252 million adults with diabetes were estimated to be undiagnosed in 2024, creating substantial future demand as diagnosis and treatment coverage improve. WHO also reported that the number of people living with diabetes increased from 200 million in 1990 to 830 million in 2022, demonstrating the long-term expansion of the disease burden. As more patients are diagnosed and require continuous disease management, demand for oral medicines, injectable therapies, insulin, and newer glucose-lowering treatments is expected to increase worldwide.

Growing Adoption of Advanced Oral and Injectable Therapies

Innovation in diabetes pharmacotherapy is strengthening market growth by providing patients and healthcare professionals with broader treatment choices and improved disease-management options. Modern diabetes treatment increasingly includes drug classes such as SGLT2 inhibitors, GLP-1 receptor agonists, DPP-4 inhibitors, and newer combination therapies, alongside established medicines such as metformin and insulin. The growing diabetes burden creates substantial potential for these therapies. IDF estimates that 635 million adults worldwide had impaired glucose tolerance in 2024, placing them at elevated risk of developing type 2 diabetes. The increasing focus on individualized treatment is also encouraging the use of therapies that can address glucose control alongside cardiovascular, kidney, or weight-management considerations where clinically appropriate. Furthermore, WHO reported that diabetes prevalence among adults aged 18 years and older increased from 7% in 1990 to 14% in 2022. Pharmaceutical companies are therefore investing heavily in new formulations, fixed-dose combinations, longer-acting medicines, and patient-friendly delivery systems. These developments can improve treatment convenience and adherence while expanding the therapeutic options available to different patient groups, supporting continued growth of the global diabetes drugs market.

Increasing Healthcare Expenditure and Improved Treatment Access

Rising healthcare spending and efforts to improve diabetes diagnosis and treatment access are creating additional opportunities for pharmaceutical manufacturers. The IDF estimates that global diabetes-related health expenditure exceeded US$1 trillion in 2024, representing approximately 12% of total global health expenditure and a 338% increase over the previous 17 years. This substantial spending reflects the growing economic importance of diabetes management and the continuing need for medicines, monitoring, and long-term care. Improved screening and diagnosis are also expanding the treated patient population. IDF estimates that 43% of adults living with diabetes, or approximately 252 million people, were undiagnosed in 2024, with almost 90% of these individuals living in low- and middle-income countries. WHO further reported that treatment coverage remains uneven, with more than half of adults with diabetes not taking medication in 2022. As governments and healthcare systems strengthen screening programs, expand access to essential medicines, and improve chronic disease management, more patients are likely to enter formal treatment pathways. This combination of higher healthcare expenditure, better diagnosis, and expanding treatment coverage is expected to support long-term diabetes drug demand.

Challenges of the Diabetes Drugs Market

High Treatment Costs and Unequal Access

The affordability of diabetes medicines remains a significant challenge, particularly in low- and middle-income countries where a large proportion of the global diabetic population resides. According to the IDF, approximately 81% of adults with diabetes live in low- and middle-income countries, while almost 90% of undiagnosed cases are also located in these economies. WHO reported that in 2022, more than half of adults living with diabetes were not taking medication, with treatment coverage lowest in low- and middle-income countries. Access barriers can include medicine prices, limited insurance coverage, inadequate healthcare infrastructure, shortages of trained healthcare professionals, and inconsistent availability of essential medicines. These issues are particularly important for patients who require lifelong therapy, including insulin. The introduction of advanced medicines can also increase treatment costs compared with older generic therapies. Consequently, although global diabetes prevalence continues to increase, rising patient numbers do not automatically translate into equivalent pharmaceutical demand when patients cannot afford or access treatment. Expanding reimbursement, strengthening public healthcare systems, improving medicine supply chains, and increasing availability of affordable generic and biosimilar options will be important for reducing these access disparities.

Side Effects, Treatment Adherence, and Complex Disease Management

Treatment adherence and concerns about medication-related side effects represent another challenge for the diabetes drugs market. Diabetes is a chronic condition requiring long-term management, and patients may need multiple medicines or treatment adjustments as the disease progresses. WHO reported that 59% of adults aged 30 years and older living with diabetes were not taking medication in 2022, demonstrating the significant gap between disease prevalence and treatment use. Treatment complexity can be affected by dosing frequency, injection requirements, monitoring needs, cost, and adverse effects. Different diabetes medicines also have different safety and tolerability considerations, requiring healthcare professionals to select therapies according to individual patient characteristics. In addition, diabetes frequently occurs alongside other chronic conditions, making medication management more complicated. WHO notes that uncontrolled diabetes can contribute to serious complications including kidney failure, blindness, heart attacks, stroke, and lower-limb amputation. These complications increase the need for comprehensive disease management rather than reliance on a single medication. Pharmaceutical companies are consequently focusing on longer-acting formulations, combination therapies, easier administration methods, and treatments with broader clinical benefits. Nevertheless, improving patient education, adherence, affordability, and continuity of care remains essential for achieving sustained growth in diabetes drug utilization.

Diabetes Drug Launches Worldwide

* Awiqli (insulin icodec) – United States, 2026: Novo Nordisk’s once-weekly basal insulin received U.S. FDA approval in March 2026 for adults with type 2 diabetes, providing an alternative to daily basal insulin injections.

* Obeda (semaglutide) – India, 2026: Dr. Reddy’s Laboratories launched Obeda, a semaglutide injection for type 2 diabetes, following DCGI approval. It was reported as the company’s first approved generic semaglutide product in India.

* Mounjaro (tirzepatide) – India, 2025: Eli Lilly launched Mounjaro in India after regulatory approval, expanding access to its dual GIP/GLP-1 receptor agonist for diabetes and weight management.

* Merilog (insulin aspart-szjj) – United States, 2025: Merilog became the first FDA-approved rapid-acting insulin biosimilar, expanding treatment options for people with diabetes.

* Kirsty (insulin aspart-xjhz) – United States, 2025: FDA approval of Kirsty marked an important milestone as an interchangeable rapid-acting insulin aspart biosimilar for diabetes treatment.

* Awiqli (insulin icodec) – China, 2025: China approved Awiqli, a once-weekly basal insulin, providing a longer-acting alternative to conventional daily basal insulin therapy for type 2 diabetes.

* Mazdutide – China, 2025: China’s NMPA approved mazdutide, a dual GLP-1/glucagon receptor agonist, for obesity and type 2 diabetes. It was reported as the world’s first drug in this dual-agonist class.

* Prusogliptin – China, 2025: China approved prusogliptin, a novel DPP-4 inhibitor, adding another oral treatment option for type 2 diabetes to the country’s growing diabetes-drug portfolio.

* Cofrogliptin – China, 2025: Cofrogliptin, another DPP-4 inhibitor, received regulatory approval in China in February 2025, expanding the country’s range of oral glucose-lowering medicines.

* Ozempic (semaglutide) – India, 2025: Novo Nordisk launched Ozempic in India in December 2025, bringing its widely used once-weekly GLP-1 diabetes treatment to one of the world’s largest diabetes populations.

Growing Need for Lifelong Insulin Therapy

The diabetes insulin drugs market is a major segment of diabetes therapeutics because insulin is essential for survival in people with type 1 diabetes and is also required by some people with advanced type 2 diabetes. The International Diabetes Federation estimates that 589 million adults aged 20–79 years were living with diabetes worldwide in 2024, with this number projected to reach 853 million by 2050. The expanding diabetic population is therefore creating sustained demand for human insulin, insulin analogues, biosimilar insulin, and different delivery formats. Modern insulin products include rapid-, short-, intermediate-, long-, and ultra-long-acting formulations, allowing treatment to be tailored to individual requirements. IDF also highlights that insulin remains an essential treatment option when non-insulin therapies do not achieve adequate glycemic control in type 2 diabetes. However, access remains a significant issue; IDF estimates that only about half of people with type 2 diabetes who could benefit from insulin have access to appropriate insulin therapy, due to cost, supply-chain, regulatory, and device-related barriers. Increasing diagnosis, improved treatment coverage, and development of biosimilar and patient-friendly insulin products are expected to support market expansion.

Convenient Oral Therapy Supports DPP-4 Inhibitor Demand

The diabetes DPP-4 inhibitors drugs market is supported by the continued need for convenient oral glucose-lowering therapies, particularly for patients with type 2 diabetes. DPP-4 inhibitors work by blocking the dipeptidyl peptidase-4 enzyme and are used to improve blood glucose control. The IDF Diabetes Atlas identifies DPP-4 inhibitors as one of the established oral medication classes used in type 2 diabetes management. Type 2 diabetes accounts for more than 90% of diabetes cases worldwide, creating a large potential population for oral therapies. Evidence from the LANDMARC study in India also illustrates continued use of these medicines: DPP-4 inhibitor use among participants increased from 48.9% at baseline to 62.4% after 36 months, while biguanides remained widely prescribed at 92.2%. DPP-4 inhibitors are generally administered orally and can be incorporated into combination treatment strategies when a single medication does not provide adequate glucose control. Continued growth in diagnosed type 2 diabetes, demand for oral treatment, combination therapies, and patient-focused medication regimens is expected to maintain demand for this drug class.

Insulin Dependence Creates Consistent Treatment Demand Type 1 Diabetes Drugs

The type 1 diabetes drugs market is characterized by the essential requirement for insulin-based treatment. Unlike type 2 diabetes, type 1 diabetes occurs when the body can no longer produce sufficient insulin, and IDF states that people with type 1 diabetes require insulin treatment for survival. Consequently, insulin remains the foundation of pharmacological management, while technologies and supportive therapies increasingly complement treatment. The market includes rapid-acting, short-acting, intermediate-acting, long-acting, and combination insulin products, allowing healthcare professionals to tailor treatment according to individual glucose patterns and lifestyles. IDF’s 2024 estimates indicate that 589 million adults aged 20–79 years were living with diabetes globally, although type 1 diabetes represents a smaller proportion of total diabetes cases than type 2. The type 1 segment is also supported by innovations in insulin delivery, including insulin pumps, continuous glucose monitoring integration, and automated insulin-delivery approaches. Improved diagnosis and management among children and adolescents further strengthen long-term demand because treatment continues throughout life. Research into improved insulin formulations, biosimilars, delivery devices, and disease-modifying approaches may further influence the market. However, affordability and reliable insulin availability remain important challenges, particularly in lower-resource healthcare systems.

Expanding Type 2 Diabetes Population Drives Oral Medication Adoption

The oral diabetes drugs market is one of the most widely used segments of diabetes therapeutics because oral medicines provide convenient treatment options for many patients with type 2 diabetes. The IDF reports that type 2 diabetes accounts for more than 90% of diabetes cases worldwide, creating a substantial patient population requiring glucose-lowering medication. Oral therapies include metformin, sulfonylureas, DPP-4 inhibitors, SGLT2 inhibitors, thiazolidinediones, alpha-glucosidase inhibitors, and other agents. IDF guidance indicates that when lifestyle changes are insufficient to control glucose levels, oral medication is generally initiated, with metformin commonly used as a first-line medicine. The overall diabetes population is also expanding rapidly, reaching 589 million adults in 2024 and projected to reach 853 million by 2050. This demographic expansion creates substantial long-term demand for oral therapies. Combination treatments are also becoming increasingly important when one medication does not provide sufficient glycemic control. Improvements in formulation, fixed-dose combinations, treatment personalization, and medicines offering additional cardiovascular or kidney benefits are expected to strengthen the oral diabetes drugs segment.

Hospital-Based Treatment Supports Specialized Diabetes Drug Distribution

The diabetes drugs hospital pharmacies market plays an important role in supplying medicines to patients receiving inpatient and specialized diabetes care. Hospital pharmacies provide access to insulin, injectable and oral glucose-lowering medicines, emergency treatments, and medications required for patients with complex diabetes-related conditions. The growing global disease burden is strengthening this distribution channel. IDF estimates that 589 million adults aged 20–79 years were living with diabetes in 2024, while diabetes-related health expenditure reached at least US$1 trillion globally during the same year. Hospitals are particularly important for patients experiencing severe hyperglycemia, diabetic emergencies, surgical requirements, infections, or complications affecting the kidneys, cardiovascular system, and other organs. Hospital pharmacists and multidisciplinary care teams also contribute to medication selection, dosage management, treatment transitions, and patient education. Increasing diagnosis rates and the rising number of people requiring long-term diabetes management are supporting pharmaceutical demand across hospital settings. At the same time, hospitals are increasingly adopting digital prescription systems, medication-management platforms, and inventory-control technologies to improve medicine availability and reduce dispensing errors. Growth in specialized diabetes centers and hospital-based chronic disease programs is expected to further support the hospital pharmacy segment worldwide.

High Disease Burden and Rapid Adoption of Innovative Therapies in the United States

United States diabetes drugs market remains one of the most developed and valuable markets globally, supported by a large diabetic population, substantial healthcare expenditure, and rapid adoption of advanced therapies. According to the International Diabetes Federation, approximately 38.4 million adults in the U.S. were living with diabetes in 2024, representing about 13.7% of the adult population. Demand is increasingly shifting toward innovative therapies, particularly GLP-1 receptor agonists, SGLT-2 inhibitors, and combination treatments, supported by growing clinical evidence and physician acceptance. The country also benefits from extensive pharmaceutical R&D and a strong pipeline of novel diabetes medicines. Continuous glucose monitoring and other digital health technologies are increasingly being integrated into diabetes management, enabling more personalized treatment decisions. Insurance coverage and value-based healthcare initiatives can improve access to modern therapies, although high out-of-pocket costs remain a barrier for some patients. The U.S. regulatory environment also supports innovation through established approval pathways, allowing new diabetes treatments and formulations to reach the market efficiently. These factors collectively reinforce the country’s position as a major center for diabetes drug innovation and commercialization.

Strong Healthcare Infrastructure and Evidence-Based Treatment in Germany

Germany diabetes drugs market is supported by a well-established healthcare system, broad medical coverage, and strong awareness of diabetes management. Germany has one of Europe’s largest populations, with approximately 7–9 million people estimated to have diagnosed diabetes, according to commonly reported national health estimates. The country’s aging demographic structure is an important factor supporting long-term pharmaceutical demand because diabetes prevalence generally increases with age. Physicians increasingly use advanced drug classes, including GLP-1 receptor agonists and SGLT-2 inhibitors, particularly when treatment goals are not achieved with conventional therapies or when additional cardiovascular or kidney-related benefits are relevant. Germany’s evidence-based clinical guidelines and structured healthcare system also support early diagnosis, regular monitoring, and combination therapy. However, pharmaceutical pricing regulations and health technology assessments can influence reimbursement and the speed at which premium therapies are adopted. Increasing use of digital health tools, remote monitoring, and patient-centered disease-management programs is creating additional opportunities for pharmaceutical treatment optimization. As obesity, aging, and chronic disease management remain important healthcare priorities, demand for effective diabetes medicines is expected to remain steady. The country’s strong medical infrastructure and reimbursement framework will continue to support market development.

China Patient Population and Expanding Treatment Access

China diabetes drugs market is expanding rapidly due to the country’s enormous diabetic population, improving healthcare infrastructure, and increasing diagnosis and treatment rates. The International Diabetes Federation estimates that approximately 148 million adults aged 20–79 years were living with diabetes in China in 2024, making the country one of the world’s largest diabetes markets. Growing urbanization, sedentary lifestyles, dietary changes, and increasing obesity are contributing to the continuing disease burden. Government efforts to strengthen chronic disease screening and management are helping more patients enter formal treatment pathways. Wider reimbursement coverage has also improved access to several modern therapies, including SGLT-2 inhibitors and DPP-4 inhibitors, while GLP-1-based treatments are gaining attention because of their glucose-lowering and weight-management benefits. Domestic pharmaceutical companies are increasing investment in diabetes R&D and generic drug production, creating more cost-effective treatment alternatives. Hospital expansion and digital healthcare platforms are also improving access to diabetes management in both urban and developing regions. Nevertheless, significant differences in healthcare access and treatment availability remain between major cities and rural areas. Continued healthcare modernization, rising diagnosis rates, and expanding pharmaceutical availability are expected to drive China’s diabetes drug market over the long term.

High Diabetes Prevalence and Healthcare Modernization Drive Saudi Arabia Demand

The Saudi Arabia diabetes drugs market is benefiting from high diabetes prevalence, increasing health awareness, and significant investment in healthcare infrastructure. According to the International Diabetes Federation, approximately 2.6 million adults aged 20–79 years in Saudi Arabia were living with diabetes in 2024, representing a substantial share of the country’s adult population. The high disease burden creates consistent demand for insulin, oral glucose-lowering medicines, and newer therapies. Adoption of GLP-1 receptor agonists and SGLT-2 inhibitors is increasing as healthcare professionals seek treatments that can provide effective glucose management and, where appropriate, additional weight, cardiovascular, or kidney-related benefits. Government investment in healthcare modernization and chronic disease programs is improving screening, diagnosis, and treatment access. Expansion of private hospitals, specialty clinics, and insurance-supported healthcare services is also creating additional distribution channels for advanced medicines. However, dependence on imported pharmaceutical products and differences in affordability can restrict access to some premium therapies. Saudi Arabia’s broader healthcare transformation under Vision 2030 is encouraging investment in digital health, preventive care, and specialized medical services. As diabetes prevention and chronic disease management remain national healthcare priorities, increasing treatment coverage and adoption of modern therapies are expected to support continued growth in the Saudi diabetes drugs market.

Recent Developments in Diabetes Drugs Market

• October 2025-The U.S. FDA accepted an expedited review for Tzield, a treatment designed to delay the onset of stage 3 type 1 diabetes in adults and children aged eight and older. The decision highlights growing regulatory support for early-intervention diabetes therapies.
• July 2025 – Biocon Biologics received FDA approval for Kirsty (insulin aspart-xjhz), the first interchangeable biosimilar to NovoLog. The therapy is indicated for glycemic control in both adult and pediatric patients, expanding access to affordable insulin options.
• July 2024 – Novo Nordisk A/S received a Complete Response Letter (CRL) from the FDA regarding its Biologics License Application for once-weekly basal insulin icodec. The agency requested additional information before reconsidering approval.
• March 2024 – Eli Lilly and Company partnered with Amazon Pharmacy to distribute its GLP-1 drugs through Amazon and Truepill. This move increased global accessibility to Lilly’s injectable GLP-1 medications, including Mounjaro and Zepbound.
• January 2024 – Glenmark Pharmaceuticals Ltd. launched Lirafit, a biosimilar version of liraglutide, in India. The drug is priced at roughly USD 1.21 per day for a standard 1.2 mg dose, making GLP-1 therapy more affordable for local patients.
• June 2023 – Pfizer Inc. announced that the company continued the clinical development of its oral GLP-1-RA candidate for the treatment of adults suffering from type 2 diabetes and obesity.
• March 2023 - Sanofi (India) received marketing authorization for its diabetes drug Soliqua (in a pre-filled pen) from the Central Drugs Standard Control Organization (CDSCO) in India
• February 2023: Akums Drugs and Pharmaceutical Limited, a contract drug manufacturing company, announced the launch of the ‘Lobeglitazone’ drug for the treatment of type 2 diabetes in India.